Study of Aritinercept in Patients With Generalized Myasthenia Gravis (NCT07596901)
A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients With Generalized Myasthenia Gravis
🩺 Plain-English Summary (8th-Grade Level)
This clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effectiveness, pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) of aritinercept.
Who can join: Review the eligibility criteria below.
Location: Aurinia Investigational Site — Pasadena, California
Age range: 18 Years to 85 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- Aurinia Investigational Site — Pasadena, California
- Aurinia Investigational Site — Altamonte Springs, Florida
- Aurinia Investigational Site — Boca Raton, Florida
- Aurinia Investigational Site — Homestead, Florida
- Aurinia Investigational Site — Miami, Florida
- Aurinia Investigational Site — Miami, Florida
- Aurinia Investigational Site — Chicago, Illinois
- Aurinia Investigational Site — O'Fallon, Illinois
- Aurinia Investigational Site — Dearborn, Michigan
- Aurinia Investigational Site — Flint, Michigan
- Aurinia Investigational Site — Houston, Texas
📞 Contact the Study Coordinator
Phone: (833) 606-5975
Email: clinicaltrials@auriniapharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Myasthenia Gravis, Generalized
- Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) — Carlsbad, California
- A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC) — Phoenix, Arizona
- A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE) — Boca Raton, Florida
- A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis — Mission Hills, California
Explore by condition: All Myasthenia Gravis, Generalized clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.